This Solid Tumor solution covers DNA panel of 42 genes and RNA panel
of 137 gene fusions. Genomic DNA and RNA are extracted from
patient’s FFPE sample. Target enriched libraries are sequenced using
Illumina sequencing platform.
NGS data are interpreted on a certified platform by detecting,
annotating and pre-classifying SNVs, indels in all genes in the panel,
TERT promoter mutations C228T and C250T, MSI(2) status in 6 unique
loci associated with colorectal cancer: BAT-25, BAT-26, CAT-25, NR-21,
NR-22 and NR-27, gene amplification events in 24 genes: ALK, BRAF,
CDK4, CDKN2A, EGFR, ERBB2, FBXW7, FGFR1, FGFR2, FGFR3, HRAS,
KIT, KRAS, MET, MYOD1, NRAS, PDGFRA, PIK3CA, RAF1, ROS1, RET,
SF3B1, TERT and TP53, and including 137 RNA fusions in addition to
MET exon 14 skipping and EGFR variant III.
Specimen Type: FFPE tissue block with > 50% tumour percentage
LTAT: 1 Month
To become the leading regional healthcare testing provider by offering unique screening and diagnostic solutions that better the nature of conventional healthcare services.